BackBellevue Life Sciences Acquisition - Warrants (09/02/2028) Overview

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Other Current Liabilities

Track Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s other current liabilities ($18M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$17.66M
29.89% YoYΔ $4.06M vs prior year quarter

Peer average

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Other Current Liabilities History

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) vs. peers: Other Current Liabilities Comparison

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) (BLACW) FAQ

The latest other current liabilities for BLACW is $18M as of March 2026. That compares with $14M in the prior-year period — up 29.9% year over year. Investors often review this figure alongside Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BLACW's other current liabilities moved from $14M to $18M — a 29.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s operating scale or balance-sheet position.

A other current liabilities figure of $18M for BLACW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BLACW's other current liabilities ($18M), review year-over-year change from $14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.